Oramed Pharmaceuticals Inc. (ORMP)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $4.16
- As of
Kresmion compiles this page from ORMP's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
ORAMED PHARMACEUTICALS INC. (ORMP): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-17.
See the full ORMP dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ORMP on one page. Preview it with sample data, then open it live with a free account.
Preview the ORMP dossierActive events for ORMP
- mediumEarnings above estimates
Q2-2026: Beat consensus by 319.5%, EPS $1.84 vs $0.4386 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 87% of ORMP (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 78% of ORMP (2026Q2)
- medium13F: new position
MILLENNIUM MANAGEMENT LLC new position in ORMP
- lowEarnings above estimates
Q2-2025: EPS $0.31 vs $-0.0408 estimate, +0.35 on a near-zero consensus
FREE, NO ACCOUNT
Every event on ORMP, as it fires
You are seeing 5 of 8 events recorded on ORMP since 2026-05-24.
The five above landed across 4 days. The other 3 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ORMP (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 68403P203 · 2026Q2 | $884K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 68403P203 · 2026Q2 | $200K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 68403P203 · 2026Q2 | $105K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ORMP
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ORMP against its peers
ORMP's operating margin of -754.4% ranks in the 28th percentile of 19 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ORMP | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 2.0M USD | 17.0M USD | 19 | 17 |
| Gross margin | 0.7% | 67.2% | 6 | 7 |
| Operating margin | -754.4% | -279.5% | 28 | 19 |
| Net margin | 3202.5% | -229.6% | 98 | 19 |
| Return on equity | 32.1% | -49.6% | 89 | 21 |
| P / E | 2.8x | n/a | n/a | 2 |
Peers (24): TRDA, PEPG, KRRO, IVVD, ACOG, XGN, IPHA, PRQR, ADAG, ALXO, WHWK, DTIL, CGEN, ELDN, RNAC, YARW, CHRS, MDWD, EVMN, STRO, NGEN, NAGE, SION, NBP. Left out: SCNLD (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ORMP: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ORMP on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ORMP for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.